


**WE CLAIM:**

1. A compound selected from Formula Ia, Ib, Ic, Id and Ie:



in which:

$n$  is selected from 0, 1 and 2;  $m$  is selected from 0, 1, 2 and 3;

$W$  is selected from  $-NR_4-$ ,  $-S-$ ,  $-O-$ ,  $-S(O)-$  and  $-S(O)_2-$ ; wherein  $R_4$  is selected from hydrogen and  $C_{1-6}$ alkyl;

$R_1$  is selected from  $C_{6-10}$ aryl- $C_{0-4}$ alkyl,  $C_{5-10}$ heteroaryl- $C_{0-4}$ alkyl,  $C_{3-12}$ cycloalkyl- $C_{0-4}$ alkyl and  $C_{3-8}$ heterocycloalkyl- $C_{0-4}$ alkyl; wherein any arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl of  $R_1$  is optionally substituted by 1 to 3 radicals independently selected from halo, nitro, cyano,  $C_{6-10}$ aryl,  $C_{5-10}$ heteroaryl,  $C_{3-12}$ cycloalkyl,  $C_{3-8}$ heterocycloalkyl,  $C_{1-6}$ alkyl,  $C_{1-6}$ alkoxy, halo-substituted- $C_{1-6}$ alkyl, halo-substituted- $C_{1-6}$ alkoxy,  $-XNR_5R_5$ ,  $-XNR_5XNR_5R_5$ ,  $-XNR_5XOR_5$ ,  $-XOR_5$ ,  $-XSR_5$ ,  $-XS(O)R_5$ ,  $-XS(O)_2R_5$ ,  $-XC(O)NR_5R_5$ ,  $-XOXR_6$  and  $-XC(O)R_6$ ; wherein  $X$  is a bond or  $C_{1-6}$ alkylene;  $R_5$  is selected from hydrogen,  $C_{1-6}$ alkyl and  $C_{3-12}$ cycloalkyl- $C_{0-4}$ alkyl; and  $R_6$  is selected from  $C_{3-8}$ heterocycloalkyl- $C_{0-4}$ alkyl and  $C_{5-10}$ heteroaryl- $C_{0-4}$ alkyl optionally substituted by 1 to 3 radicals selected from  $C_{1-6}$ alkyl and  $-C(O)OH$ ; wherein any aryl, heteroaryl, cycloalkyl or heterocycloalkyl substituent of  $R_1$  is further optionally substituted by 1 to 5 radicals independently selected from  $C_{1-6}$ alkyl and  $C_{1-6}$ alkoxy;

$R_2$  is selected from  $C_{6-10}$ aryl- $C_{0-4}$ alkyl,  $C_{5-10}$ heteroaryl- $C_{0-4}$ alkyl,  $C_{3-12}$ cycloalkyl- $C_{0-4}$ alkyl and  $C_{3-8}$ heterocycloalkyl- $C_{0-4}$ alkyl; wherein any arylalkyl, heteroarylalkyl, cycloalkylalkyl or heterocycloalkylalkyl of  $R_2$  is optionally substituted by 1 to 3 radicals

independently selected from halo, nitro, cyano, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkenyl, C<sub>1-6</sub>alkynyl, C<sub>1-6</sub>alkoxy, halo-substituted-C<sub>1-6</sub>alkyl, halo-substituted-C<sub>1-6</sub>alkoxy, C<sub>3-8</sub>heteroaryl-C<sub>0-4</sub>alkyl, -XNR<sub>5</sub>R<sub>5</sub>, -XOR<sub>5</sub>, -XSR<sub>5</sub>, -XS(O)R<sub>5</sub>, -XS(O)<sub>2</sub>R<sub>5</sub>, -XSNR<sub>5</sub>R<sub>5</sub>, -XS(O)NR<sub>5</sub>R<sub>5</sub>, -XS(O)<sub>2</sub>NR<sub>5</sub>R<sub>5</sub>, -XC(O)OR<sub>5</sub>, -XOC(O)R<sub>5</sub>, -XC(O)R<sub>5</sub>, -XC(O)NR<sub>5</sub>XNR<sub>5</sub>R<sub>5</sub>, -XC(O)NR<sub>5</sub>R<sub>5</sub>, -XC(O)NR<sub>5</sub>XC(O)OR<sub>5</sub>, -XC(O)NR<sub>5</sub>XNR<sub>5</sub>C(O)R<sub>5</sub>, -XC(O)NR<sub>5</sub>XNR<sub>5</sub>C(O)OR<sub>5</sub>, -XC(O)NR<sub>5</sub>XOR<sub>5</sub>, -XC(O)N(XOR<sub>5</sub>)<sub>2</sub>, -XNR<sub>5</sub>C(O)R<sub>5</sub>, -XC(O)NR<sub>5</sub>R<sub>6</sub>, -XC(O)R<sub>6</sub>, -XR<sub>7</sub>, -XC(O)R<sub>7</sub>, -XR<sub>6</sub> and -XC(O)NR<sub>5</sub>XR<sub>7</sub>; wherein X is a bond or C<sub>1-6</sub>alkylene; and R<sub>5</sub> is selected from hydrogen, C<sub>1-6</sub>alkyl and C<sub>3-12</sub>cycloalkyl-C<sub>0-4</sub>alkyl; R<sub>6</sub> is selected from C<sub>3-8</sub>heterocycloalkyl-C<sub>0-4</sub>alkyl and C<sub>5-10</sub>heteroaryl-C<sub>0-4</sub>alkyl optionally substituted by 1 to 3 radicals selected from C<sub>1-6</sub>alkyl and -C(O)OH; and R<sub>7</sub> is selected from halo and cyano;

R<sub>3</sub> is selected from halo, hydroxy, -XSR<sub>5</sub>, -XS(O)R<sub>5</sub>, -XS(O)<sub>2</sub>R<sub>5</sub>, -XC(O)R<sub>5</sub> and -XC(O)OR<sub>5</sub>; wherein X is a bond or C<sub>1-6</sub>alkylene; and R<sub>5</sub> is selected from hydrogen, C<sub>1-6</sub>alkyl and C<sub>3-12</sub>cycloalkyl-C<sub>0-4</sub>alkyl; and the pharmaceutically acceptable salts, hydrates, solvates, isomers and prodrugs thereof.

2. The compound of claim 1 in which:

W is selected from -NR<sub>4</sub>- and -O-; wherein R<sub>4</sub> is selected from hydrogen and C<sub>1-6</sub>alkyl;

R<sub>1</sub> is selected from C<sub>6-10</sub>aryl-C<sub>0-4</sub>alkyl and C<sub>5-10</sub>heteroaryl-C<sub>0-4</sub>alkyl; wherein any arylalkyl and heteroarylalkyl of R<sub>1</sub> is optionally substituted by 1 to 3 radicals independently selected from halo, nitro, C<sub>5-10</sub>heteroaryl, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy, halo-substituted-C<sub>1-6</sub>alkyl, -XNR<sub>5</sub>R<sub>5</sub>, -XOR<sub>5</sub>, -XSR<sub>5</sub>, -XNR<sub>5</sub>XNR<sub>5</sub>R<sub>5</sub>, -XNR<sub>5</sub>XOR<sub>5</sub>, -XC(O)NR<sub>5</sub>R<sub>5</sub>, -XOXR<sub>6</sub> and -XC(O)R<sub>6</sub>; wherein X is a bond or C<sub>1-6</sub>alkylene; R<sub>5</sub> is selected from hydrogen, C<sub>1-6</sub>alkyl and C<sub>3-12</sub>cycloalkyl-C<sub>0-4</sub>alkyl; and R<sub>6</sub> is selected from C<sub>3-8</sub>heterocycloalkyl-C<sub>0-4</sub>alkyl and C<sub>5-10</sub>heteroaryl-C<sub>0-4</sub>alkyl optionally substituted by 1 to 3 radicals selected from C<sub>1-6</sub>alkyl and -C(O)OH; wherein any heteroaryl substituent of R<sub>1</sub> is further optionally substituted by 1 to 5 C<sub>1-6</sub>alkyl radicals;

R<sub>2</sub> is selected from C<sub>6-10</sub>aryl-C<sub>0-4</sub>alkyl and C<sub>5-10</sub>heteroaryl-C<sub>0-4</sub>alkyl; wherein any arylalkyl or heteroarylalkyl of R<sub>2</sub> is optionally substituted by 1 to 3 radicals independently selected from halo, nitro, cyano, C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkenyl, C<sub>1-6</sub>alkoxy, halo-substituted-C<sub>1-6</sub>alkyl, C<sub>3-8</sub>heteroaryl-C<sub>0-4</sub>alkyl, -XNR<sub>5</sub>R<sub>5</sub>, -XOR<sub>5</sub>, -XSR<sub>5</sub>, -XS(O)<sub>2</sub>NR<sub>5</sub>R<sub>5</sub>, -XC(O)OR<sub>5</sub>, -XOC(O)R<sub>5</sub>, -

$\text{XC(O)NR}_5\text{XNR}_5\text{R}_5$ ,  $-\text{XC(O)NR}_5\text{XC(O)OR}_5$ ,  $-\text{XC(O)NR}_5\text{XNR}_5\text{C(O)R}_5$ ,  $-\text{XC(O)NR}_5\text{XNR}_5\text{C(O)OR}_5$ ,  $-\text{XC(O)NR}_5\text{XOR}_5$ ,  $-\text{XC(O)N(XOR}_5)_2$ ,  $-\text{XNR}_5\text{C(O)R}_5$ ,  $-\text{XC(O)NR}_5\text{R}_6$ ,  $-\text{XC(O)R}_6$ ,  $-\text{XR}_7$ ,  $-\text{XR}_6$  and  $-\text{XC(O)NR}_5\text{XR}_7$ ; wherein X is a bond or  $\text{C}_{1-6}$ alkylene; and  $\text{R}_5$  is selected from hydrogen,  $\text{C}_{1-6}$ alkyl and  $\text{C}_{3-12}$ cycloalkyl- $\text{C}_{0-4}$ alkyl;  $\text{R}_6$  is selected from  $\text{C}_{3-8}$ heterocycloalkyl- $\text{C}_{0-4}$ alkyl and  $\text{C}_{5-10}$ heteroaryl- $\text{C}_{0-4}$ alkyl optionally substituted by 1 to 3 radicals selected from  $\text{C}_{1-6}$ alkyl and  $-\text{C(O)OH}$ ; and  $\text{R}_7$  is cyano; and

$\text{R}_3$  is selected from halo, hydroxy,  $-\text{XC(O)R}_5$  and  $-\text{XC(O)OR}_5$ ; wherein X is a bond or  $\text{C}_{1-6}$ alkylene; and  $\text{R}_5$  is selected from hydrogen,  $\text{C}_{1-6}$ alkyl and  $\text{C}_{3-12}$ cycloalkyl- $\text{C}_{0-4}$ alkyl.


3. The compound of claim 1 in which W is selected from  $-\text{NH}-$  and  $-\text{O}-$ ; and  $\text{R}_1$  is selected from phenyl, benzyl, 5,6,7,8-tetrahydro-naphthalenyl, benzo[1,3]dioxolyl, 1H-indazol-7-yl, indan-4-yl and 1H-indolyl; wherein any arylalkyl and heteroarylalkyl of  $\text{R}_1$  is optionally substituted by 1 to 3 radicals independently selected from methoxy, methyl, amino, halo, hydroxymethyl, hydroxy, quinoxaliny, ethyl, pyridinyl, methoxy-phenyl, piperazinyl-carbonyl, ethyl-(2-hydroxy-ethyl)-amino 2-(4-methyl-piperazin-1-yl)-ethoxy, formamyl, isopropyl, methyl-sulfanyl, tri-fluoro-methyl, ethoxy, 3-isopropylamino-propylamino, dimethyl-amino, morpholino, cyclopropyl-methoxy, butoxy, cycloheptyl-oxy and 1,4,5,7-tetramethyl-pyrrolo[3,4-d]pyridazinyl.

4. The compound of claim 1 in which  $\text{R}_2$  is selected from pyridinyl, phenyl, thiazolyl, pyridinyl-methyl, pyridinyl-ethyl, thiophenyl, benzyl, quinolinyl, 7-oxo-5,6,7,8-tetrahydro-naphthalenyl, naphthyl and pyrimidinyl; wherein any arylalkyl or heteroarylalkyl of  $\text{R}_2$  is optionally substituted by 1 to 3 radicals independently selected from halo, nitro, cyano, methyl, propyl-sulfamoyl, methyl-sulfamoyl, methoxy, methyl-carboxy, 2-dimethylamino-ethyl-formamyl, carboxy, amino, cyano-ethyl, cyano-methyl, ethenyl, tri-fluoro-methyl, hydroxy-methyl, ethyl, methyl-sulfanyl, butyl, isobutyl, carboxy-methyl-formamidyl, 1-carboxy-ethyl-formamidyl, carboxy-ethyl, amino-ethyl-formamidyl, amino-propyl-formamidyl, dimethyl-amino-ethyl-formamidyl, dimethyl-amino-propyl-formamidyl, dimethyl-amino-butyl-formamidyl, methyl-formamidyl, ethyl-formamidyl, ethyl-formamidyl-methyl, 2-(2-dimethylamino-ethylcarbonyl)-ethyl, 2-(2-dimethylamino-formamidyl)-ethyl, 2-(amino-ethyl-formamidyl)-ethyl, 2-(amino-propyl-formamidyl)-ethyl, 2-(propyl-formamidyl)-ethyl, amino-

propyl-formamidyl-methyl, 2-(methyl-amino-carbamoyl)-ethyl, 2-(ethyl-amino-carbamoyl)-ethyl, morpholino-ethyl-formamidyl, morpholino-carbonyl-methyl, amino-ethyl-formamidyl-methyl, cyclobutyl-formamidyl, methyl-formamidyl-methyl, dimethyl-formamidyl-methyl, hydroxy-ethyl-formamidyl-methyl, hydroxy-propyl-formamidyl-methyl, N,N-bis-(3-hydroxy-propyl)-formamidyl, cyclopentyl-formamidyl, isobutyl-formamidyl, isobutyl-formamidyl-methyl, cyclopentyl-formamidyl-methyl, cyano-ethyl-formamidyl, cyano-methyl-formamidyl, pyrrolidinyl-ethyl-formamidyl, 2-(isobutyl-formamidyl)-ethyl, 1H-tetrazolyl, 2-(1H-tetrazol-5-yl)-ethyl, 2-(1H-tetrazol-5-yl)-methyl, 2-(1-methyl-1H-tetrazol-5-yl)-methyl, acetyl-amino, cyclopropyl-formamidyl-methyl, hydroxy-ethyl-formamidyl, hydroxy-propyl-formamidyl, propyl-formamidyl-methyl, ethoxy-propyl-formamidyl, acetyl-amino-ethyl-formamidyl, 1-methyl-piperidin-4-yl-formamidyl, morpholino-carbonyl-ethyl, methoxy-carbonyl-methyl, methoxy-carbonyl-ethyl-formamidyl, methoxy-carbonyl-ethyl-formamidyl-methyl, methoxy-carbonyl-methyl-formamidyl-methyl, methoxy-carbonyl-methyl-formamidyl, 4-amino-cyclohexyl-formamidyl, 4-amino-cyclohexyl-formamidyl-methyl, acetyl-amino-ethyl-formamidyl-methyl, ethoxy-propyl-formamidyl-methyl, methoxy-carbonyl-ethyl, 1-formyl-pyrrolidin-2-yl-carboxylic acid, (1-carboxy-3-methyl-butyl)-formamidyl, 2-(methoxy-carbonyl-methyl-formamidyl)-ethyl, 1-carboxy-(2,2-dimethyl-propyl)-formamidyl, 3-tert-butoxycarbonyl-amino-propyl-formamidyl, acetoxymethyl and 1-carboxy-ethyl-formamidyl.

5. The compound of claim 1 in which n is 0 or 1; m is 0 or 1; and R<sub>3</sub> is selected from halo, hydroxy, -C(O)OH and -C(O)OCH<sub>3</sub>.

6. The compound of claim 1 of Formula Ig:



Ig

in which R<sub>2</sub> is selected from pyridinyl, phenyl, thiazolyl, pyridinyl-methyl, pyridinyl-ethyl, thiophenyl, benzyl, quinolinyl, 7-oxo-5,6,7,8-tetrahydro-naphthalenyl, naphthyl and pyrimidinyl; wherein any arylalkyl or heteroarylalkyl of R<sub>2</sub> is optionally substituted by 1 to 3

radicals independently selected from halo, nitro, cyano, methyl, propyl-sulfamoyl, methyl-sulfamoyl, methoxy, methyl-carboxy, 2-dimethylamino-ethyl-formamyl, carboxy, amino, cyano-ethyl, cyano-methyl, ethenyl, tri-fluoro-methyl, hydroxy-methyl, ethyl, methyl-sulfanyl, butyl, isobutyl, carboxy-methyl-formamidyl, 1-carboxy-ethyl-formamidyl, carboxy-ethyl, amino-ethyl-formamidyl, amino-propyl-formamidyl, dimethyl-amino-ethyl-formamidyl, dimethyl-amino-propyl-formamidyl, dimethyl-amino-butyl-formamidyl, methyl-formamidyl, ethyl-formamidyl, ethyl-formamidyl-methyl, 2-(2-dimethylamino-ethylcarbamoyl)-ethyl, 2-(2-dimethylamino-formamidyl)-ethyl, 2-(amino-ethyl-formamidyl)-ethyl, 2-(amino-propyl-formamidyl)-ethyl, 2-(propyl-formamidyl)-ethyl, amino-propyl-formamidyl-methyl, 2-(methyl-amino-carbamoyl)-ethyl, 2-(ethyl-amino-carbamoyl)-ethyl, morpholino-ethyl-formamidyl, morpholino-carbonyl-methyl, amino-ethyl-formamidyl-methyl, cyclobutyl-formamidyl, methyl-formamidyl-methyl, dimethyl-formamidyl-methyl, hydroxy-ethyl-formamidyl-methyl, hydroxy-propyl-formamidyl-methyl, N,N-bis-(3-hydroxy-propyl)-formamidyl, cyclopentyl-formamidyl, isobutyl-formamidyl, isobutyl-formamidyl-methyl, cyclopentyl-formamidyl-methyl, cyano-ethyl-formamidyl, cyano-methyl-formamidyl, pyrrolidinyl-ethyl-formamidyl, 2-(isobutyl-formamidyl)-ethyl, 1H-tetrazolyl, 2-(1H-tetrazol-5-yl)-ethyl, 2-(1H-tetrazol-5-yl)-methyl, 2-(1-methyl-1H-tetrazol-5-yl)-methyl, acetyl-amino, cyclopropyl-formamidyl-methyl, hydroxy-ethyl-formamidyl, hydroxy-propyl-formamidyl, propyl-formamidyl-methyl, ethoxy-propyl-formamidyl, acetyl-amino-ethyl-formamidyl, 1-methyl-piperidin-4-yl-formamidyl, morpholino-carbonyl-ethyl, methoxy-carbonyl-methyl, methoxy-carbonyl-ethyl-formamidyl, methoxy-carbonyl-ethyl-formamidyl-methyl, methoxy-carbonyl-methyl-formamidyl-methyl, methoxy-carbonyl-methyl-formamidyl, 4-amino-cyclohexyl-formamidyl, 4-amino-cyclohexyl-formamidyl-methyl, acetyl-amino-ethyl-formamidyl-methyl, ethoxy-propyl-formamidyl-methyl, methoxy-carbonyl-ethyl, 1-formyl-pyrrolidin-2-yl-carboxylic acid, (1-carboxy-3-methyl-butyl)-formamidyl, 2-(methoxy-carbonyl-methyl-formamidyl)-ethyl, 1-carboxy-(2,2-dimethyl-propyl)-formamidyl, 3-tert-butoxycarbonyl-amino-propyl-formamidyl, acetoxymethyl and 1-carboxy-ethyl-formamidyl.

7. A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 1 in combination with a pharmaceutically acceptable excipient.

8. A method for treating a disease in an animal in which inhibition of kinase activity can prevent, inhibit or ameliorate the pathology and/or symptomology of the disease, which method comprises administering to the animal a therapeutically effective amount of a compound of Claim 1.

9. The method of claim 7 in which the kinase is selected from FAK, Abl, BCR-Abl, PDGF-R, c-Kit, NPM-ALK, Flt-3, JAK2 and c-Met.

10. The use of a compound of claim 1 in the manufacture of a medicament for treating a disease in an animal in which the kinase activity of FAK, Abl, BCR-Abl, PDGF-R, c-Kit, NPM-ALK, Flt-3, JAK2 and/or c-Met contributes to the pathology and/or symptomology of the disease.